

**The Investigation of the Active Sites of Monoamine Oxidase (MAO) A  
and B and the Study of MAO-A Mediated Neurotoxicity Using 4-  
Substituted Tetrahydropyridines.**

by

Sonya L. Palmer

Dissertation submitted to the Faculty of the Virginia Polytechnic Institute and  
State University in partial fulfillment of the requirements for the degree of

Doctor of Philosophy

in

Chemistry

Approved By:

---

Dr. Neal Castagnoli, Jr., Chairman

---

Dr. David G. I. Kingston

---

Dr. James M. Tanko

---

Dr. Harold Bell

---

Dr. James Wolfe

May, 1998

Blacksburg, Virginia

**The Investigation of the Active Sites of Monoamine Oxidase (MAO)  
A and B and the Study of MAO-A Mediated Neurotoxicity Using 4-  
Substituted Tetrahydropyridines.**

by

Sonya L. Palmer

Professor Neal Castagnoli, Jr., Chairman

**ABSTRACT**

The mitochondrial membrane bound flavoenzymes monoamine oxidase A and B (MAO-A and MAO-B) catalyze the  $\alpha$ -carbon oxidation of a variety of amines including neurotransmitters such as dopamine and serotonin. Although the primary structures of these enzymes have been established from the corresponding gene sequences, relatively little is known regarding the structural features of the active sites which lead to the selectivities observed with various substrates and inhibitors. In spite of many efforts, these enzymes have not been crystallized. In the absence of X-ray structures, the design, synthesis, and evaluation of biological activity remain the only way to assess a view of the active sites, through SAR and QSAR studies. The excellent MAO-A and/or B substrate and inhibitor properties of various 1,4-disubstituted-1,2,3,6-tetrahydropyridine derivatives offer an interesting opportunity to probe the active sites of MAO-A and MAO-B. In an effort to explore the spatial features of the active sites, we have synthesized series of substituted tetrahydropyridines, evaluated their biological activity with purified MAO-A and MAO-B, and carried out a topological analysis of the MAO active sites using molecular modeling. In addition, the results described in this thesis provide evidence that the MAO-A

and MAO-B active sites differ in shape, regions of activity, and areas that tolerate polar interactions.

The role of MAO in neurodegenerative processes such as Parkinson's Disease has been recognized for some time. The structurally unique parkinsonian inducing substrate 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) is bioactivated to neurotoxic metabolites. The mechanism of neurotoxicity has been studied extensively and it is known that MAO-B catalyzes the conversion of MPTP to the 2,3-dihydro-1-methyl-4-phenylpyridinium species (MPDP<sup>+</sup>) which undergoes further oxidation to the neurotoxic metabolite 1-methyl-4-phenyl pyridinium (MPP<sup>+</sup>). However, the role of MAO-A in mediating a neurotoxic response, has not been fully defined due to the lack of selective MAO-A substrates. In this thesis, we have investigated the neurotoxic potential of several tetrahydropyridines in C57Bl/6 mice and the ability of selective inhibitors to protect against the expression of MAO mediated neurotoxicity.

**This thesis is dedicated to my mother Ethelene Brown Palmer and my father the late Leroy Palmer for all their endless love, support and encouragement for all these years.**

## **ACKNOWLEDGMENTS**

I wish to express my gratitude and appreciation to Professor Neal Castagnoli, Jr. for his guidance and encouragement. His insightful advise, patience, understanding, and support have made a lasting impression. He is a mentor from whom I learned not only science but the appreciation of life.

A special tribute is given to Mrs. Kay Castagnoli for her help, support, and assistance with my research at Virginia Tech.

Grateful acknowledgments are also made to Dr. Harold Bell, Dr. David Kingston, Dr. James Tanko, and Dr. James Wolfe for their valuable advice and assistance.

Many thanks to the members of the Castagnoli research group for their suggestions, assistance, and friendship.

I wish to express special thanks to my good friend Dr. Stéphane Mabic who has provided professional and personal support that have made my graduate experience more enjoyable.

I also wish to thank the NIH and the Harvey W. Peters Research Center for the study of Parkinson's Disease and Disorders of the Central Nervous System for supporting my research.

## Table of Contents

<b>Chapter</b>	<b>Page</b>
1. Introduction (Literature review)	1
1.1. Parkinson's disease	1
1.2. MPTP - A parkinsonian inducing agent	2
1.2.1. Discovery and background	2
1.2.2. Proposed mechanism of MPTP neurotoxicity	4
1.2.3. Structure-activity relationships	9
1.3. MAO-A and MAO-B	10
1.3.1. Enzyme characteristics of MAO-A and B	10
1.3.2. Distribution of MAO A and MAO-B in the CNS	12
1.3.3. Roles of MAO A and MAO-B in the CNS	14
1.3.4. Endogenous substrates (catecholamines and aminoalkyl indoles)	16
1.3.5. MAO substrates	18
1.3.6. MAO inhibitors	19
1.4. Proposed mechanisms of monoamine oxidase catalysis	21
1.4.1. Single electron transfer	21
1.4.2. Hydrogen atom transfer	24
1.4.3. Polar addition -elimination pathway	25
2. Research proposal and background	27
2.1. Steric parameters that influence enzyme selectivity	27
2.2. Molecular modeling of the active sites of MAO-A and MAO-B and their relation to endogenous MAO substrates	34
2.3. Investigation of MAO-A mediated neurotoxicity	38
2.4. Investigation of the neuroprotection of 7-nitroindazole using the	

MPTP model of neurotoxicity	41
2.5. Research rationale and proposals	45
3. Evaluation of steric parameters that influence substrate and inhibitor properties of C-4 substituted tetrahydropyridines.	47
3.1. 1-Methyl and 1-cyclopropyl-4-biphenyl substituted tetrahydropyridines	50
3.2. Chemistry	50
3.3. Enzymology	54
3.4. Discussion	66
3.5. Molecular modeling of the biphenyl series	69
3.5.1. Topological analysis of the MAO-A and MAO-B active sites	69
3.5.2. Discussion	71
3.5.3. Validation of topological analysis using tetrahydropyridines	73
3.5.4. Synthesis of 1-methyl-4-(3-indolyl)-1,2,3,6-tetrahydropyridine	74
3.5.5. Enzymology	75
3.5.6. Molecular modeling	77
4. Evaluation of the neurotoxicity of 1-methyl-4-(4-phenylphenyl)-1,2,3,6-tetrahydropyridine	80
4.1. In vivo C57-B16 mouse experiments	82
4.2. Results	85
4.3. Conclusions	91
5. Evaluation of other tetrahydropyridinyl analogs for potential neurotoxicity	93
5.1. Compounds and rationale	95

5.2. In vivo experiments and results	97
5.3. Discussion	106
6. Evaluation of the neuroprotection of the reported selective neuronal nitric oxide synthase inhibitor 7-nitroindazole using the MPTP model of neurotoxicity	113
6.1. Research rationale and background	113
6.2. In vivo experiments and results	116
6.3. Discussion	132
7. Efforts toward docking the endogenous MAO substrates in the MAO-A and MAO-B active site models developed using tetrahydropyridinyl derivatives	136
7.1. Rationale for the selection of the hydroxylated tetrahydropyridinyl derivatives	140
7.2. Synthesis of the hydroxylated derivatives	143
7.3. Enzymology	151
7.4. Molecular modeling of the hydroxylated tetrahydropyridinyl analogs	161
7.4.1. Modeling of dopamine and the docking of dopamine in the active site	167
7.4.2. Modeling of serotonin and the docking of serotonin in the active site	173
7.5. Discussion	177
7.6. Preliminary efforts toward the docking of norepinephrine and epinephrine in the MAO active site models	178
7.6.1. Synthesis of 3-hydroxy-1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine.	180
7.6.2. Enzymology	181



7.6.3. Discussion	184
8. Summary and conclusions	185
8.1. MAO-A and MAO-B active sites	185
8.2. MAO catalyzed neurotoxicity in mice	186
8.3. Evaluation of 7-NI neuroprotection	187
9. Experimental	188
9.1. Chemistry	188
9.1.1. 1-Methyl- and 1-cyclopropyl-4-aryl-substituted tetrahydropyridines	188
9.1.2. 1-Methyl C4 hydroxylated tetrahydropyridines	197
9.2. Enzymology	202
9.3. Toxicity studies and in vivo 7-nitroindazole experimental	204
10. References	207

## List of Schemes

<b>Scheme</b>	<b>Page</b>
1. The Origin of MPTP from MPPP	3
2. MAO Catalyzed Oxidation of MPTP	7
3. Proposed Radical Mechanism for MAO Catalysis	22
4. Proposed MAO Inactivation Pathway for Cyclopropylamines	23
5. Proposed Polar Addition-Elimination Mechanism	26
6. NOS Catalyzed Oxidation of L-Arginine to L-Citrulline and Nitric Oxide	42
7. The Proposed Mechanism of the NOS Catalyzed Oxidation of L-Arginine	
8a. Synthesis of C4 Substituted Piperidinols ( <b>121-130</b> )	52
8b. Synthesis of C4 Substituted Tetrahydropyridine Analogs ( <b>131-140</b> )	53
9. Synthesis of 1-Cyclopropyl-4-piperidone	54
10. Metabolic Fate of <b>132</b> and <b>133</b> when Incubated with MAO	58
11. Proposed SET Pathway for the Inactivation of MAO by 1-Cyclopropyl-4-phenyl-1,2,3,6-tetrahydropyridine ( <b>145</b> )	65
12. Synthesis of 1-Methyl-4-(3-indolyl)-1,2,3,6- tetrahydropyridine ( <b>147</b> )	74
13. Metabolic Fate of <b>147</b> when Incubated with MAO-B	76
14. Metabolic Fate of <b>88</b> when Incubated with MAO-B	81
15. Metabolic Fate of <b>156</b> when Incubated with MAO-B	97
16. Metabolic Fate of <b>159</b> when Incubated with MAO-B	97
17. The Intermediates Involved in the MAO Catalyzed Oxidation of Tetrahydropyridines	110

18.	Possible Metabolic Fate of 1-Methyl-4-phenyl-3-tetrahydropyridinol derivative <b>230</b>	180
19.	Synthesis of 4' and 3' Hydroxyl MPTP Derivatives <b>173</b> and <b>177</b>	144
20.	Synthesis of the 2' Hydroxyl MPTP Analog <b>180</b>	145
21.	Synthesis of <i>p</i> -, <i>m</i> -, and <i>o</i> -Methoxy MPTP Derivatives <b>183</b> , <b>186</b> , and <b>189</b>	146
22.	Synthesis of 3- and 2-(Hydroxymethyl)phenyl Substituted MPTP Derivatives <b>193</b> and <b>197</b>	148
23.	Synthesis of the 3,4-Benzodioxane Derivative of MPTP <b>201</b>	149
24.	Synthesis of 5-Methoxy-3-indolyl and 5-Hydroxy-3-indolyl Tetrahydropyridine Derivatives <b>204</b> and <b>205</b>	151
25.	Proposed Metabolic Fate of <b>173</b> , <b>177</b> , and <b>180</b> When Incubated with MAO	153
26.	Proposed Metabolic Fate of <b>183</b> , <b>186</b> , <b>189</b> , <b>193</b> and <b>197</b> When Incubated with MAO	154
27.	Proposed Metabolic Fate of <b>201</b> When Incubated with MAO	155
28.	Proposed Metabolic Fate of <b>204</b> and <b>205</b> When Incubated with MAO	155
29.	Synthesis of 3-Hydroxy-1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine ( <b>230</b> )	182

## List of Tables

Table	Page
1. Selectivities of the Endogenous Substrates with MAO-A and MAO-B	17
2. MAO-A and B Activity of Various MPTP Derivatives	30
3. Summary of the Effect of DMSO on the Ability of MAO to Catalyze the Oxidation of a Substrate	55
4. Kinetic Data Obtained for the MAO-A Catalyzed Oxidation of 1-Methyl-4-(2-phenylphenyl)-1,2,3,6-tetrahydropyridine ( <b>133</b> )	60
5. $V_{max}$ and $K_m$ Values for the MAO-A and MAO-B Catalyzed Oxidation of Various 4-Aryl-1-methyl-1,2,3,6-tetrahydropyridine Derivatives	62
6. $K_i$ and $k_{inact}$ Values for the Inactivation of MAO-A and MAO-B by Various 4-Aryl-1-cyclopropyl-1,2,3,6-tetrahydropyridine Derivatives	66
7. MAO-A and MAO-B Kinetic Data ( $V_{max}/K_m$ , $\text{min}^{-1}\text{mM}^{-1}$ ) of Various <i>meta</i> - and <i>ortho</i> -Phenyl Substituted MPTP Analogs	69
8a. The Initial Rates of MAO-B catalyzed conversion of <b>147</b> to <b>148</b>	75
8b. In Vivo Toxicity of 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine at a Dosage of 238 mmol/Kg	86
9. Preliminary ICR White Mice Experiments with 1-Methyl-4-(4-phenylphenyl)-1,2,3,6-tetrahydropyridine ( <b>133</b> )	87
10. Dosing Protocols for 1-Methyl-4-(4-phenylphenyl)-1,2,3,6-tetrahydropyridine ( <b>133</b> ) in C57Bl/6 Mice	88
11a. Dopamine Depletion Studied Using 1-Methyl-4-(	

	4-phenylphenyl)-1,2,3,6-tetrahydropyridine ( <b>133</b> ) at a Dosage of 58.9 $\mu$ moles/Kg	89
11b.	Dopamine Depletion Studied Using 1-Methyl-4-(4-phenylphenyl)-1,2,3,6-tetrahydropyridine ( <b>133</b> ) at a Dosage of 73.6 $\mu$ moles/Kg	89
12.	Neuroprotection Experiment with 1-Methyl-4-(4-phenylphenyl)-1,2,3,6-tetrahydropyridine ( <b>133</b> )	90
13.	$V_{max} / K_m$ Values for the MAO-A and MAO-B Catalyzed Oxidation of Various 4-Substituted-1-methyl-1,2,3,6-tetrahydropyridine Derivatives	96
14.	Dosing Protocols for 1-Methyl-4-(1-pyrrolyl)-1,2,3,6-tetrahydropyridine ( <b>156</b> )	99
15.	Dopamine Depletion Studied Using 1-Methyl-4-(1-pyrrolyl)-1,2,3,6-tetrahydropyridine ( <b>156</b> ) at a Dosage of 118.92 $\mu$ moles/Kg	99
16.	Dopamine Depletion Studied Using 1-Methyl-4-(1-pyrrolyl)-1,2,3,6-tetrahydropyridine ( <b>156</b> ) at a Dosage of 79.28 $\mu$ moles/Kg	100
17.	Dosing Protocols for 1-Methyl-4-(3-methylfuran-2-yl)-1,2,3,6-tetrahydropyridine ( <b>159</b> )	101
18.	Dopamine Depletion Studied Using 1-Methyl-4-(3-methylfuran-2-yl)-1,2,3,6-tetrahydropyridine ( <b>159</b> ) at a Dosage of 93.54 $\mu$ moles/Kg	102
19.	Dopamine Depletion Studied Using 1-Methyl-4-(3-methylfuran-2-yl)-1,2,3,6-tetrahydropyridine ( <b>159</b> ) at a Dosage of 149.66 $\mu$ moles/Kg	102
20.	Dosing Protocols for 1-Methyl-4-(3-indolyl)-	

	1,2,3,6-tetrahydropyridine ( <b>147</b> )	103
21.	Dopamine Depletion Studied Using 1-Methyl-4-(3-indolyl)-1,2,3,6-tetrahydropyridine ( <b>147</b> ) at a Dosage of 66.15 $\mu$ moles/Kg	104
22.	Dosing Protocols for 1-Propargyl-4-(1-methylpyrrol-2-yl)-1,2,3,6-tetrahydropyridine ( <b>162</b> )	105
23.	Dopamine Depletion Studied Using 1-Propargyl-4-(1-methylpyrrol-2-yl)-1,2,3,6-tetrahydropyridine ( <b>162</b> ) at a Dosage of 137.8 $\mu$ moles/Kg	105
24.	Dopamine Depletion Studied Using 1-Propargyl-4-(1-methylpyrrol-2-yl)-1,2,3,6-tetrahydropyridine ( <b>162</b> ) at a Dosage of 68.65 $\mu$ moles/Kg	106
25.	The Energy Differences in Kcal/mol Between the DP <sup>+</sup> and the DHP Species of Several Neurotoxic Tetrahydropyridine Analogs	111
26.	Log P Values for Various Neurotoxic Analogs	112
27.	Summary of the Analyte Recovery Experiment, Analyte Tissue Binding Experiment, and Analyte Extraction Experiment	119
28.	Striatal MPP <sup>+</sup> and 7-NI Concentrations in MPTP (238 $\mu$ mol/Kg) Treated C57Bl/6 Mice Pretreated with Increasing Doses of 7-NI	121
29.	Striatal MPP <sup>+</sup> Concentrations in C57Bl/6 Mice Pretreated s.c. with 273 $\mu$ mol/Kg 7-NI Prior to Increasing Doses of i.p. MPTP	122
30a.	Striatal MPTP, MPDP <sup>+</sup> , MPP <sup>+</sup> , and 7NI Concentrations in	

	C57Bl/6 Control Mice	123
30b.	Striatal MPTP, MPDP+, MPP+, and 7NI Concentrations in C57Bl/6 Treated Mice	124
31.	C57Bl/6 Mice (n=6) Treated with 7-NI in Peanut Oil (s.c., 273 $\mu\text{mol/Kg}$ ) and Sacrificed at the Indicated Time Post Injection	125
32.	Striatal Dopamine and DOPAC Concentrations in C57Bl/6 Mice (n=9) After Treatment as Indicated	127
33.	The Evaluation of the Role of 7-NI in MPTP Induced Neurotoxicity (Experiment 1)	129
34.	The MPP+ Levels in C57Bl/6 Mice Treated with 238 $\mu\text{mol/Kg}$ MPTP $\cdot\text{HCl}$ and Sacrificed at 4, 8, and 24 hrs	130
35.	The Evaluation of the Contributing Components of 7-NI Neuroprotection Against MPTP Toxicity (Experiment 2)	131
36a.	Summary of Dihydropyridinium Intermediates Monitored to Obtain Kinetic Parameters for Various Polar Tetrahydropyridinyl Derivatives	158
36b.	$V_{\text{max}}$ and $K_{\text{m}}$ Values for the MAO-A and MAO-B Catalyzed Oxidation of Various Polar 4-Substituted 1-methyl-1,2,3,6- tetrahydropyridine Derivatives	159
37.	The Dihedral Angles and Energies of the Ten Minimum Energy Conformers of Dopamine	168

## List of Figures

<b>Figure</b>		<b>Page</b>
1.	The Mechanism of MPTP Neurotoxicity	8
2.	The MAO-A and MAO-B Active Sites Models Proposed by Efang and Boudreau	37
3.	UV Scans of an Incubation Mixture Containing 0.5 mM 1-Methyl-4-(3'-phenylphenyl)-1,2,3,6-tetrahydropyridine and 0.08 $\mu$ M MAO-B	57
4.	The Lineweaver-Burke Double Reciprocal Plot for the MAO-B Catalyzed Oxidation of 1-Methyl-4-(3-phenylphenyl)-1,2,3,6-tetrahydropyridine ( <b>132</b> )	58
5.	The Lineweaver-Burke Double Reciprocal Plot for the MAO-A Catalyzed Oxidation of 1-Methyl-4-(2-phenylphenyl)-1,2,3,6-tetrahydropyridine	61
6.	Plot of $\ln$ [% enzyme activity remaining] Versus Time for the MAO-A Inactivation by 1-Cyclopropyl-4-( $\alpha$ -naphthyl)-1,2,3,6-tetrahydropyridine	64
7.	The Double Reciprocal Plot for the MAO-A Inactivation by 1-Methyl-4-( $\alpha$ -naphthyl)-1,2,3,6-tetrahydropyridine	65
8.	MAO-A Active (blue) and Inactive (green) Area	71
9.	MAO-B Active (pink) and Inactive (green) Area	71
10.	Minimum Sizes of MAO-B and MAO-A Active Sites Defined Using Biphenyl Derivatives	72
11.	Superimposition of the 4-(3-Phenyl)phenoxy (Red) and 4-(2-Phenyl)phenyl (Blue) Derivatives <b>96</b> and <b>133</b>	73
12.	The Lineweaver-Burke Double Reciprocal Plot for the MAO-B Catalyzed Oxidation of <b>147</b>	76



13 a & b.	Docking of the 3-Indolyl Derivative <b>147</b> in MAO-A and MAO-B Active Sites Showing the Interaction with the Inactive Area (green) of MAO-A	78
14.	Comparison of the Sizes of 3-Methoxyphenyl <b>43</b> (blue) and 3-Indolyl <b>147</b> (red) Derivatives	79
15.	Standard HPLC Tracing for Dopamine Analysis	84
16.	Dopamine Calibration Curve	85
17.	LC-DA Tracings from Extracts of Mouse Striata Obtained from 7-NI and MPTP Treated Animals (Panels A-F)	115
18a.	The Front and Side View of the MAO-A Active Site Generated Using Substituted Tetrahydropyridines	139
18b.	The Front and Side View of the MAO-B Active Site Generated Using Substituted Tetrahydropyridines	139
19.	Analysis of with <b>177</b> with MAO-B	156
20.	Analysis of with <b>180</b> with MAO-B	156
21.	Analysis of with <b>180</b> with MAO-A	156
22.	Analysis of with <b>186</b> with MAO-B	156
23.	Analysis of with <b>189</b> with MAO-B	156
24.	Analysis of with <b>189</b> with MAO-A	156
25.	Analysis of with <b>193</b> with MAO-B	157
26.	Analysis of with <b>193</b> with MAO-A	157
27.	Analysis of with <b>197</b> with MAO-B	157
28.	Analysis of with <b>197</b> with MAO-A	157
29.	Analysis of with <b>201</b> with MAO-B	157
30.	Analysis of with <b>204</b> with MAO-B	157
31.	Analysis of with <b>204</b> with MAO-A	158
32.	Analysis of with <b>205</b> with MAO-A	158

33a.	The Superimposition of the Minimum Energy Conformers of Analogs <b>173</b> and <b>193</b>	163
33b.	The Superimposition of <b>173</b> and <b>193</b> With Only the Tetrahydropyridinyl Template and the van der Waals Volume Represented	164
34.	The Polar Mapping of the MAO-B Active Site	165
35.	The Polar Mapping of the MAO-A Active Site	166
36.	The Defined Angles of Dopamine ( <b>8</b> )	168
37.	The Minimum Energy Conformers of Dopamine ( <b>8-A</b> and <b>8-B</b> )	170
38.	The Superimposition of Dopamine and MPTP	171
39a.	The Docking of Dopamine in the MAO-B Active Site	172
39b.	The Docking of Dopamine in the MAO-A Active Site	173
40.	The Minimum Energy Conformers of Serotonin	175
41.	The Superimposition of Serotonin ( <b>12-A</b> ) and the (5-hydroxyindol-3-yl) Derivative <b>205</b>	177
42a.	The Docking of Serotonin in the MAO-A active Site	178
42b.	The Docking of Serotonin in the MAO-B active Site	179
43.	Scans of 1-Methyl-3-hydroxy-4-phenyl-1,2,3,6-tetrahydropyridine ( <b>230</b> ) with MAO-B	184
44a & 44b.	Control Scans of <b>230</b> With MAO-B ( <b>44a</b> - Left) and Scans of <b>230</b> With Deprenyl Treated MAO-B ( <b>44b</b> - Right)	185

## **List of Charts**

<b>Charts</b>	<b>Page</b>
1. Series of Flexible MPTP Analogs	29
2. A Series of Cis and Trans 1-Methyl-4-substituted-1,2,3,6-tetrahydropyridines	32
3. A Series of 4-Aryloxy (panel A) and 4-Substituted-phenoxy (panel B) Tetrahydropyridines	33
4. A Series of 1-Methyl and 1-Cyclopropyl-4-Aryl-Substituted Tetrahydropyridines	49
5. MPTP Analogs Investigated for the Ability to Produce Selective Dopaminergic Neurotoxicity in Mice	95
6. Target Hydroxylated 1-Methyl-4-substituted-1,2,3,6-tetrahydropyridines	142